Divalproex Sodium
Product Images NDC 58118-0042

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 58118-0042). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Dr 250mg

Packaging label for Divalproex Sodium DR 250 mg tablets from Clinical Solutions Wholesale, LLC. The label indicates a quantity of 30 tablets. It includes barcode, NDC 58118-0040-8, manufacturer information including Unichem Pharmaceuticals, Hasbrouck Heights, NJ, and batch number SAMPLE456 with expiration date 2021 Sep.*

FDA Label Image

Structure (Divalproextablets Figure 01)

Chemical structure of divalproex sodium, showing the sodium salt form of valproic acid with its characteristic branched alkyl chains and carboxylate groups. The structure illustrates the repeating polymeric unit with the sodium ion.*

FDA Label Image

Comparison Of Percentage Of Patient Separated By Study (Divalproextablets Figure 02)

A bar chart comparing percentage values between two categories labeled PBO and DVPX across two studies, Study 1 (YMRS) and Study 2 (MRS). The percentages for DVPX are notably higher in both studies, reaching 60% in Study 1 and 58% in Study 2, while PBO percentages are 26% and 29%, respectively.*

FDA Label Image

% Reduction In Cps Rate Vs % Of Patients (Divalproextablets Figure 03)

A line chart comparing the percentage reduction in Clinical Rating Scale (CRS) rate between Divalproex Sodium and placebo among patients. The x-axis represents the percent of patients, and the y-axis shows the percent reduction in CRS rate ranging from -100% to 100%, with indicators for worsening, no change, and improvement. The solid line represents Divalproex Sodium, showing greater improvement compared to the dashed placebo line.*

FDA Label Image

% Reduction In Cps Rate Vs % Of Patients (Divalproextablets Figure 04)

A cumulative distribution graph comparing the percentage of patients by percentage reduction in complex partial seizure (CPS) rate on the x-axis. Two dose groups, high dose (solid line) and low dose (dashed line), are plotted. The y-axis represents improvement versus worsening in CPS rate, with a midpoint indicating no change. The graph shows the distribution of response to treatment by dose level.*

FDA Label Image

Mean 4-week Migraine Rates (Divalproextablets Figure 05)

A bar chart comparing Placebo and Divalproex Sodium treatments across two studies. The vertical axis represents a measured variable with values ranging from 0 to 6. Study 1 shows a higher value for Placebo compared to Divalproex Sodium. Study 2 also shows Placebo having a higher value than Divalproex Sodium, but both studies indicate a reduction with Divalproex Sodium treatment.*

FDA Label Image

Company Logo (Divalproextablets Figure 06)

FDA Label Image

Divalproex Sodium Dr 500mg Tablet 30 Count Blister Card (Divalproextablets Figure 09)

Label for Divalproex Sodium DR 500 mg Tablets from Clinical Solutions Wholesale, LLC. The label includes the NDC number 58118-0042-8 and manufacturing details by Unichem Pharmaceuticals in Hasbrouck Heights, NJ. It also shows batch and lot numbers, packaging date (Sep 2018), and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.